IL-12, IL-15, and IL-18 have demonstrated the ability to activate NK cells against hepatocellular carcinoma (HCC), melanoma, and breast cancer [[9], [10], [11], [12]]. This evidence concerns the gene IL18 and hepatocellular carcinoma.